



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cirtuvivint

Cat. No.:	HY-137435
CAS No.:	2143917-62-6
Molecular Formula:	C ₂₄ H ₂₅ N ₇ O
Molecular Weight:	427.5
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 12.5 mg/mL (29.24 mM; ultrasonic and warming and heat to 60°C) H ₂ O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	2.3392 mL	11.6959 mL	23.3918 mL
		5 mM	0.4678 mL	2.3392 mL	4.6784 mL
		10 mM	0.2339 mL	1.1696 mL	2.3392 mL
		Please refer to the solubility information to select the appropriate solvent.			
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (2.92 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (2.92 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research ^[1] .
In Vitro	Cirtuvivint (SM08502) inhibits serine and arginine rich splicing factor (SRSF) phosphorylation and disrupted spliceosome activity, which is associated with inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibition of gene expression includes effects on alternative splicing ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Orally administered Cirtuvivint (SM08502) significantly inhibits growth of gastrointestinal tumors and decreased SRSF

phosphorylation and Wnt pathway gene expression in xenograft mouse models^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA